THE US Food and Drug Administration has approved Gamifant (emapalumab-izsg) for the treatment of pediatric and adult patients with rare immune system disorder primary hemophagocytic lymphohistiocytosis (HLH) - the first drug specifically for the condition.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Nov 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Nov 18